Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro , smashing analysts’ expectations in the face of Eli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.
Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.
Novo Nordisk Tirzepatide Zepbound Mounjaro Ozempic Wegovy Weight Loss Earnings Profit
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billionEli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly stock pops on annual guidance hike, strong Q2 top and bottom lineEli Lilly stock pops on annual guidance hike, strong Q2 top and bottom line
Read more »
Eli Lilly, Robinhood and Zillow rose premarket; Warner Bros, Fastly, Bumble fallEli Lilly, Robinhood and Zillow rose premarket; Warner Bros, Fastly, Bumble fall
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »